Table 2.
Comparison between worsening and not worsening non-ICU COVID-19 patients
| WG n = 12 (31%) | NWG n = 27 (69%) | P value | |
| Male, n (%) | 8 (67%) | 11 (41%) | P = 0.21 |
| Age (years) | 71 (60–79) | 52 (42–72) | P = 0.01 |
| Comorbidities | |||
| Hypertension | 6 (50%) | 7 (26%) | P = 0.24 |
| Diabetes | 5 (42%) | 5 (19%) | P = 0.26 |
| Pneumopathy | 0 | 2 (7%) | P = 0.73 |
| Heart disease | 4 (33%) | 2 (7%) | P = 0.21 |
| Active malignancy | 1 (8%) | 0 | P = 0.68 |
| Other immunosuppression | 0 | 1 (4%) | P = 0.87 |
| Chronic kidney disease | 1 (8%) | 1 (4%) | P = 0.82 |
| CRP (mg/dL) | 5.3 (4–8) | 4.5 (2–7,6) | P = 0.42 |
| Ferritin | 632 (292–1,451) | 431 (180–636) | P = 0.09 |
| D-dimer | 650 (400–1,025) | 500 (400–1,100) | P = 0.84 |
| Hospital length of stay (days) | 11 (8–22) | 6 (3–10) | P = 0.001 |
| Days of symptoms | 6 (4–10) | 8 (6–11) | P = 0.22 |
| Supplemental oxygen | 6 (50%) | 9 (33%) | P = 0.42 |
| Causes of worsening | |||
| Increased oxygen requirements | 7 (58%) | ||
| Progression of radiological pulmonary infiltrates | 7 (58%) | ||
| Increased inflammation biomarkers∗ | 8 (66%) | ||
| Immunomodulatory treatment | |||
| Corticosteroids | 8 (67%) | ||
| Tocilizumab | 5 (42%) | ||
| Anakinra | 2 (17%) | ||
| Siltuximab | 1 (8%) | ||
| More than 1 treatment | 3 (24%) | ||
Data are expressed as median (interquartile range) or absolute count (percentage).
∗
Defined as increased CRP and/or ferritin levels above twice the baseline levels.
CRP indicates C-reactive protein; NWG, non-worsening group; WG, worsening group.